International
The Morning Science

What science found today

‹
 

Research

Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC

Nature ·

The Brief

  • A study reports that targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression in HPV-negative head and neck squamous cell carcinoma (HNSCC).
  • The study reports that this approach improves response to anti-PD-L1 therapy in HPV-negative HNSCC.

Why it matters

It suggests that targeting fibroblasts, rather than tumour cells alone, could make anti-PD-L1 immunotherapy more effective in HPV-negative head and neck cancer.

Who’s affected

  • cancer researchers
  • clinicians treating head and neck cancer

Timeline

  1. Study published in npj Precision Oncology (nature.com feed)

  2. Biological sciences : nature.com subject feeds

    Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC

How do you feel about this?

0 Comments

    Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC – The Morning Science